A Randomized, Double-blind, Double-dummy, Two Period, Two Treatment Cross-over Pharmacodynamic and Pharmacokinetic Study of Clopidogrel Given as 5-day Repeated Oral Doses (300 mg Loading Dose Followed by 75 mg/Day and 600 mg Loading Dose Followed by 150 mg/Day) in 4 Different Groups of CYP2C19 Genotyped Healthy Male and Female Subjects.

Trial Profile

A Randomized, Double-blind, Double-dummy, Two Period, Two Treatment Cross-over Pharmacodynamic and Pharmacokinetic Study of Clopidogrel Given as 5-day Repeated Oral Doses (300 mg Loading Dose Followed by 75 mg/Day and 600 mg Loading Dose Followed by 150 mg/Day) in 4 Different Groups of CYP2C19 Genotyped Healthy Male and Female Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Dec 2011

At a glance

  • Drugs Clopidogrel (Primary)
  • Indications Acute coronary syndromes; Angina pectoris; Atherosclerosis; Cardiovascular disorders; Congenital heart defects; Embolism and thrombosis; Heart failure; Ischaemic heart disorders; Myocardial infarction; Peripheral arterial occlusive disorders; Stroke; Unstable angina pectoris
  • Focus Pharmacodynamics
  • Sponsors Sanofi
  • Most Recent Events

    • 27 Aug 2010 Trial phase changed from IV to I as reported by ClinicalTrials.gov.
    • 18 May 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top